One of the most common and understandable questions we hear after someone is diagnosed with Chronic Kidney Disease (CKD) is ” Can CKD be reversible?”

And the honest answer is:
It depends.

CKD is a spectrum — not a single disease — and the potential to reverse or recover kidney function depends on what caused it, how early it’s caught, and how your body responds to care. Let’s unpack what “reversibility” really means in kidney terms.

CKD vs. AKI: Chronic vs. Acute

First, it’s important to distinguish between Chronic Kidney Disease (CKD) and Acute Kidney Injury (AKI):

• CKD is a long-term, often gradual decline in kidney function that persists over time. It’s typically not fully reversible, but it can often be slowed or stabilized.
• AKI is a sudden drop in kidney function that happens over hours to days, often due to dehydration, infection, medication effects, or obstruction. AKI is often reversible, especially when caught early.

Sometimes, CKD and AKI occur together. For example, someone with Stage 3 CKD who becomes dehydrated and takes ibuprofen might experience an AKI on top of their existing CKD. If that AKI is reversed, kidney function may return to its prior baseline — but not higher. This is not always the case, however, because AKI is not always reversible. Chronically damaged kidneys can have a difficult time bouncing back from additional injury.

Causes That May Be Reversible (or Partially Reversible)

Certain underlying causes of kidney damage can be treated or corrected, especially if identified early. These include:

• Obstruction (like kidney stones or enlarged prostate): If urine flow is restored, kidney function can improve.
• Dehydration or low blood volume: Fluids can help return kidneys to baseline.
• Certain autoimmune conditions (like lupus nephritis): With medication, inflammation can be reduced, preventing further damage.
• Medication toxicity (e.g., NSAIDs, some antibiotics, contrast dyes): Stopping the offending drug may allow for partial recovery.
• High blood pressure and diabetes: These can’t be “cured,” but better control can stop or slow CKD progression — and sometimes even lead to small improvements in eGFR.

However, once significant scarring (fibrosis) occurs in the kidneys, that damage is generally not reversible. Think of it like a scar on your skin — the function is lost where tissue has hardened.

What “Stabilization” Really Means

Even if your kidney function doesn’t improve numerically, holding steady is a win. Many people with CKD remain in the same stage for years — even decades — without needing dialysis. That’s thanks to:

• Blood pressure and glucose control
• Avoidance of further kidney insults
• Dietary modifications
• Adjusted medications
• Close monitoring by your care team

If your labs are consistent, symptoms are minimal, and you’re not progressing — that’s a success.

False Hope vs. Real Progress

We caution patients against miracle supplements or “kidney detox” fads that promise full reversal. These are often not supported by evidence, and some can actually be harmful. Instead, we encourage a science-backed approach that includes:

• Consistent follow-up
• Shared decision-making with your provider
• Addressing reversible factors early
• Lifestyle adjustments that support overall kidney health

There’s no quick fix, but there is a path forward — and in many cases, room for optimism.

The Takeaway

Not all kidney damage is permanent — especially when caused by short-term or reversible triggers. But in chronic cases, the focus shifts from “Can I go back to normal?” to “How can I stay where I am — or slow down the clock?”

Ask your provider about the cause of your CKD and whether any part of it might be reversed or improved. It’s a conversation worth having. A deep-dive into AKI can be found at the widely regarded KDIGO archive

References

1. Kellum JA, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary. Crit Care. 2013;17(1):204.
2. Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379(9811):165–180.

For patients, families, and even healthcare providers, recognizing the signs of acute kidney injury (AKI) can prevent misdiagnosis, unnecessary fear, and missed opportunities for full recovery. This article outlines the key differences, categories, and steps you can take when kidney numbers suddenly change.

What Is Acute Kidney Injury?

Acute kidney injury refers to a sudden and often temporary loss of kidney function. It may develop over hours or days — typically in response to illness, dehydration, medications, or obstruction. AKI is diagnosed based on:

• A sudden rise in serum creatinine
• A decrease in urine output
• A change from recent baseline labs

Importantly, AKI is not the same as CKD. While CKD evolves gradually and persists for over three months, AKI can often be reversed if the cause is identified and addressed early.

The Three Categories of Acute Kidney Injury

1. Prerenal Acute Kidney Injury

This form of AKI results from reduced blood flow to the kidneys. This is usually diagnosed by careful history taking and physical examination. Common causes include:

• Dehydration (vomiting, diarrhea, heat exposure)
• Blood loss (trauma, surgery)
• Heart failure or low blood pressure
• Medications like NSAIDs, diuretics, or ACE inhibitors during illness

When caught early, prerenal acute kidney injury often resolves completely with hydration and supportive care.

2. Intrinsic (Intrarenal) Acute Kidney Injury

Here, the kidney tissue itself is damaged. This category is usually assessed with laboratory results of blood and urine testing. Causes include:

• Acute tubular necrosis (due to prolonged low blood flow or toxins)
• Glomerulonephritis (immune-based inflammation)
• Acute interstitial nephritis (commonly drug-induced)
• Vasculitis or severe infections

Treatment depends on the cause, but many intrinsic cases improve if diagnosed early.

3. Postrenal Acute Kidney Injury

This type results from urine flow obstruction — pressure backs up and impairs filtration. This category is usually confirmed or excluded by imaging studies. Common culprits:

• Enlarged prostate (BPH)
• Kidney stones
• Tumors or strictures
• Neurogenic bladder

Once the obstruction is relieved, kidney function often recovers fully.

When It’s Not Really CKD

Sometimes, patients are told they have chronic kidney disease after just one abnormal lab. But CKD requires:

• Kidney dysfunction lasting over 3 months, AND
• Evidence of structural or functional abnormalities (e.g., proteinuria, abnormal imaging)

Before labeling it CKD, providers should:

• Repeat labs to confirm persistence
• Review prior records for baseline values
• Order imaging to assess kidney size and anatomy

Failure to do so may misclassify acute kidney injury as a chronic, irreversible condition.

Reversible Scenarios That Mimic CKD

Some common, often-overlooked causes of acute kidney injury include:

• Dehydration from illness or overuse of diuretics
• NSAID toxicity, especially in older adults
• Urinary retention due to BPH or medications
• Contrast dye exposure during imaging
• Early glomerulonephritis, caught before scarring
• Medication interference (e.g., biotin, trimethoprim, fenofibrate) causing falsely elevated creatinine
• Recent strenuous exercise or large protein meals before testing

These conditions often resolve with supportive care or medication adjustments. Always reassess before assuming the diagnosis is CKD.

How Providers Distinguish AKI from CKD

To determine whether kidney dysfunction is truly chronic, doctors use:

• Serial lab results over time
• Urinalysis for protein or active sediment
• Kidney ultrasound to evaluate size and structure

A return to normal labs, normal-sized kidneys, and absence of chronic signs typically indicate acute kidney injury, not CKD.

Why It Matters

Mislabeling a reversible condition like acute kidney injury as CKD can have long-term consequences:

• Unnecessary stress or fear
• Life insurance or disability misclassification
• Missed opportunity to fully restore kidney health

Conversely, correctly identifying AKI allows for:

• Timely treatment
• Potential for full recovery
• Prevention of future episodes
• Proper education and risk counseling

The Takeaway

Not every drop in kidney function means lifelong CKD. Acute kidney injury is often reversible — and catching it early can change the course of a person’s health.

If you’ve been told you have CKD after a sudden lab change, ask your doctor:

• Has this persisted for more than 3 months?
• Could this be dehydration, medication-related, or obstruction?
• Would imaging or a follow-up test help clarify?

Sometimes, the most powerful step toward healing is asking the right question.

Read more about AKI and kidney recovery here.

See the provider level primer on acute kidney injury for a deep dive at the KDIGO site.

References

1. Kellum JA, et al. Acute Kidney Injury. Lancet. 2021;398(10302):129–144.
2. KDIGO Clinical Practice Guideline for AKI. Kidney Int Suppl. 2012;2(1):1–138.

Let’s explore what prompts this decision, what to expect from the procedure, and how a tiny sample of tissue can shape your journey with chronic kidney disease (CKD) or other kidney disorders.

Not Every Case Needs a Biopsy

Most cases of chronic kidney disease can be diagnosed and managed without a biopsy. A careful combination of medical history, bloodwork, urinalysis, and imaging studies like kidney ultrasound can often tell the story. For example, diabetes, hypertension, or polycystic kidney disease usually leave characteristic footprints that are visible in lab patterns or imaging findings.

In these straightforward scenarios, adding an invasive procedure rarely changes the plan—and could introduce unnecessary risk.

When Suspicion Warrants Tissue

A kidney biopsy becomes necessary when the standard clues don’t quite fit. Imagine a patient with no history of diabetes or hypertension, yet their urine shows large amounts of protein, or their kidney function rapidly declines. Something is out of place. A biopsy offers the microscopic clarity needed to determine whether a condition like IgA nephropathy, lupus nephritis, vasculitis, or another glomerular disease is at work.

Key situations where a biopsy is typically considered include:

• Unexplained nephrotic-range proteinuria (typically >3.5 grams/day)
• Rapidly progressive glomerulonephritis (RPGN) with sudden loss of kidney function
• Hematuria with proteinuria and no clear cause
• Acute kidney injury (AKI) with unclear origin
• Suspected autoimmune disease affecting the kidneys, such as lupus
• Monitoring treatment response in known glomerular diseases

In transplant patients, biopsies are also used to evaluate rejection, drug toxicity, or recurrent disease.

What the Procedure Involves

Despite sounding intimidating, a kidney biopsy is a relatively routine outpatient procedure. Using ultrasound (or occasionally CT) guidance, a nephrologist or interventional radiologist inserts a needle into the kidney to extract tiny samples of tissue. The patient is numbed beforehand, and conscious sedation may be used for comfort.

The collected tissue is then examined by a kidney pathologist using several types of staining and microscopy. In many cases, light microscopy, immunofluorescence, and electron microscopy are all used to assess for immune complex deposition, inflammation, scarring, and damage to specific kidney structures like the glomeruli or tubules.

The entire process—from needle stick to diagnosis—typically takes 1–3 days depending on lab complexity. The results provide a histologic diagnosis and may also be graded for severity and prognosis.

What a Biopsy Can (and Can’t) Tell You

A biopsy can:

1. Confirm or rule out rare or overlapping diseases
2. Determine if active inflammation is present (and whether it’s reversible)
3. Guide treatment decisions, such as steroid or immunosuppressive therapy
4. Assess whether a condition is mild or advanced
5. Provide a clearer prognosis

However, it’s not a crystal ball. A biopsy can’t predict with certainty how fast your disease will progress, nor does it always lead to a curative treatment. In some chronic conditions, a biopsy simply confirms what’s already suspected without changing the therapeutic course. In others, it may reveal treatable inflammation and provide a powerful chance to intervene early.

Understanding the Risks

No medical procedure is without risk, and kidney biopsy is no exception. The most common complication is bleeding, which can occur around the kidney (perinephric hematoma) or in the urine (hematuria). Most cases are self-limited, but a small percentage may require hospitalization or intervention. Other rare risks include infection, injury to nearby structures, or very rarely, need for transfusion.

Your nephrologist will weigh these risks against the potential benefits. If the biopsy result is unlikely to change your management—or if the procedure itself poses undue risk—then it may be deferred in favor of close monitoring.

Making the Decision Together

The decision to undergo a kidney biopsy is rarely black-and-white. It often comes down to a nuanced conversation between patient and provider. If you’re facing that choice, ask:

• What are we trying to rule in or rule out?
• Will the result change how we treat this?
• Are there safer alternatives to consider first?

While a kidney biopsy can be a powerful diagnostic tool, the decision to proceed should never feel automatic. Informed consent means more than signing a form—it means having a thoughtful discussion between doctor and patient. The nephrologist must clearly explain why a biopsy is being considered, what information it may reveal, and how that information could affect treatment. They should also outline the risks, such as bleeding, infection, or the possibility of an inconclusive result, as well as any non-invasive alternatives that might exist.

Just as importantly, patients must be empowered to ask questions and weigh their own values and concerns. Some may choose to proceed immediately, while others may prefer to monitor and wait. Neither choice is wrong—because ultimately, the right decision is the one that aligns with the patient’s understanding, priorities, and comfort. Respecting autonomy is central to good kidney care.

Waiting for Results and Revised Plan of Care

Once the biopsy is complete and the tissue sample is analyzed, the waiting begins—often just a few days, but emotionally charged ones. The pathology report provides detailed insight into what’s happening at the microscopic level. Are there signs of inflammation, scarring, immune deposits, or structural abnormalities? These findings don’t just carry names—they carry implications. Some results may point toward conditions that are treatable with immunosuppressants, while others may reveal irreversible damage. Your nephrologist’s role is to walk you through these findings, translate the jargon into meaning, and help weigh the next steps. This is where biopsy becomes more than a procedure—it becomes a bridge between diagnosis and modification (or validation) of care plan.

Works Cited

1. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2012;2(2):139–274.
2. Fogo AB. Approach to renal biopsy. Am J Kidney Dis. 2003;42(4):826–836.
3. Hogan J, Radhakrishnan J. The Spectrum of Minimal Change Disease in Adults. Clin J Am Soc Nephrol. 2013;8(3):475–483.
4. Sethi S, D’Agati VD, Nast CC, et al. A proposal for standardized grading of chronic changes in native kidney biopsy specimens. Kidney Int. 2020;97(5):1052–1059.

Meta Description:

Curious about when a kidney biopsy is needed? Learn what this powerful diagnostic tool reveals—and when it’s worth the risk.

For decades, patients with chronic kidney disease (CKD) were routinely considered at high risk for complications from intravenous contrast agents used in imaging studies. This concern primarily focused on contrast-associated acute kidney injury (CA-AKI) and, in specific scenarios, nephrogenic systemic fibrosis (NSF) related to gadolinium exposure. Contrast risk in CKD became almost synonymous with caution, delay, and sometimes outright avoidance of contrast-enhanced imaging.

The basis for this caution was not unfounded. Early observational studies suggested that contrast administration could precipitate abrupt declines in kidney function, particularly in patients with reduced baseline glomerular filtration rate (GFR), diabetes, or concurrent nephrotoxin exposure. Over time, however, methodological limitations of these studies—such as inadequate control groups and failure to account for confounding risk factors—have been recognized.

As a result, the contemporary conversation around contrast risk in CKD is evolving. Instead of relying on blanket restrictions, clinicians are now urged to weigh the diagnostic value of contrast studies against individualized patient risk, using refined evidence and updated guidelines.

Evolution of the Risk Paradigm

The older paradigm treated CKD as a near-absolute contraindication to many contrast-enhanced procedures. Patients were often diverted to non-contrast alternatives, which could compromise diagnostic accuracy and delay care. The pendulum began to swing on contrast risk in CKD when large-scale, propensity-matched studies challenged the causality between contrast exposure and acute kidney injury in many patient populations.

For iodinated contrast, data from emergency department and inpatient settings indicated that when matched against non-contrast controls, the rates of AKI were similar. This does not mean risk is absent—particularly in patients with advanced CKD, unstable hemodynamics, or multiple insults to kidney function—but it does mean that contrast risk in CKD may have been overestimated in the past.

In the realm of gadolinium-based contrast agents (GBCAs), similar reassessment occurred. The link between certain linear gadolinium agents and NSF is now well-established, but the introduction of macrocyclic GBCAs with more stable chelation chemistry has markedly reduced this risk. This evidence supports a more individualized evaluation of contrast risk in CKD rather than an automatic deferral of enhanced imaging.

Iodinated Contrast and Acute Kidney Injury

When iodinated contrast is necessary in higher-risk patients, strategies such as isotonic volume expansion before and after the procedure, minimizing contrast dose, and avoiding unnecessary repeat exposures can help mitigate harm. Understanding contrast risk in CKD also ensures that preventive measures are applied without unnecessary delay to critical imaging.

Gadolinium-Based Contrast and Nephrogenic Systemic Fibrosis

The early 2000s brought intense concern over nephrogenic systemic fibrosis (NSF), a debilitating and potentially fatal fibrosing disorder of the skin and internal organs linked to certain gadolinium-based contrast agents (GBCAs). Risk was greatest in patients with advanced CKD (especially those on dialysis) and in those receiving high or repeated doses of less stable linear gadolinium agents. This was a different type of contrast risk in CKD as the organs at risk were not necessarily the kidneys.

Since then, the field has shifted dramatically. Macrocyclic GBCAs—designed with more stable chelation of gadolinium—demonstrate a far lower association with NSF, even in advanced CKD. Current evidence suggests that when these agents are used judiciously, the risk is exceedingly small, though caution and informed consent remain essential.

Patients with eGFR below 30 mL/min/1.73 m² should still undergo careful benefit–risk assessment before GBCA exposure, and dialysis-dependent patients should ideally receive post-procedure hemodialysis to facilitate gadolinium clearance. Yet, as with iodinated contrast, the modern understanding of contrast risk in CKD now supports a more balanced, evidence-based approach rather than absolute avoidance.

Updated KDIGO Guidance: What’s Changed and What to Do in Practice

The most recent KDIGO guidelines on acute kidney injury and CKD management reflect the evolving evidence base. Key updates regarding contrast exposure include:

• Risk Assessment Over Blanket Prohibition: KDIGO now emphasizes individualized risk stratification using factors such as eGFR, volume status, concurrent medications, and urgency of diagnostic imaging.
• Preferred Preventive Strategy: For at-risk patients, isotonic intravenous fluids—typically normal saline—remain the cornerstone of prevention, with oral hydration as an adjunct where feasible.
• Pharmacologic Prophylaxis: Agents like N-acetylcysteine, once widely used, are no longer recommended given lack of consistent benefit.
• Gadolinium Selection: When MRI contrast is required in CKD, macrocyclic agents are preferred over linear agents due to their lower propensity for gadolinium release and NSF risk.
• Avoidance of Delay: In urgent scenarios, delaying necessary imaging to await kidney function testing should be avoided if it jeopardizes patient outcomes.

Incorporating KDIGO’s updated position into daily practice helps ensure that contrast risk in CKD is approached as a modifiable concern rather than an absolute barrier to diagnostic imaging.

Patient Selection and Risk Stratification

Not every patient with CKD carries the same vulnerability to contrast-related harm. The most informative risk assessments combine laboratory data with the clinical context. For example, a patient with stage 3a CKD who is hemodynamically stable, well-hydrated, and not taking nephrotoxic drugs has a very different outlook than a patient with stage 4 CKD, active sepsis, and concurrent NSAID use.

Risk stratification tools—such as the Mehran score for coronary angiography—can help quantify likelihood of AKI, though most are procedure-specific. Regardless of the tool used, the principle remains the same: integrate kidney function, comorbidities, and procedural urgency into decision-making. This approach aligns with KDIGO’s shift from rigid exclusion criteria toward individualized, context-sensitive evaluation of contrast risk in CKD.

Modern Prevention Strategies

Prevention starts before the procedure. For at-risk patients, isotonic intravenous hydration—typically with normal saline at a rate of 1–3 mL/kg/hour before and after the study—is the most consistently effective measure. Oral hydration can supplement IV fluids when logistics or patient preference dictate, but should not replace them in high-risk scenarios.

Contrast dosing should be minimized without sacrificing diagnostic yield. This often involves using the lowest volume of contrast that will still produce adequate opacification, aided by modern low-osmolar or iso-osmolar contrast agents. Avoiding repeated contrast studies in a short time frame also reduces cumulative risk. Understanding contrast risk in CKD in the context of prevention helps reinforce why dose reduction and agent selection matter.

For gadolinium, the strategy hinges on agent selection: macrocyclic GBCAs at the lowest necessary dose, with post-procedure dialysis for those already on renal replacement therapy. Importantly, prophylactic medications such as N-acetylcysteine or high-dose statins—once popular—are no longer recommended in routine practice due to lack of proven benefit in preventing CA-AKI.

Balancing Diagnostic Benefit Against Risk

The decision to use contrast in a patient with CKD is rarely black-and-white. The benefits of enhanced imaging may include early cancer detection, accurate vascular mapping before surgery, or rapid diagnosis of life-threatening conditions. In these cases, the value of the diagnostic information can far outweigh the relatively modest and manageable risks of CA-AKI or NSF.

The modern paradigm encourages clinicians to frame the conversation around shared decision-making. Patients should understand not only the potential kidney-related risks, but also the risks of forgoing contrast-enhanced imaging—such as missed diagnoses, delayed treatment, or the need for more invasive tests. This balanced perspective ensures that contrast risk in CKD is seen within the broader context of overall patient outcomes.

Takeaway

The concept of contrast risk in CKD is undergoing a profound transformation. While vigilance remains critical—especially in advanced CKD or unstable patients—current evidence supports a more nuanced, individualized approach. Updated KDIGO guidelines reinforce this shift, urging clinicians to focus on risk stratification, preventive hydration, and appropriate agent selection rather than reflexive avoidance.

In practice, this means that contrast-enhanced imaging should not be dismissed out of hand for CKD patients. Instead, it should be approached thoughtfully, with preventive strategies in place and a clear understanding of the diagnostic benefits at stake. This evolving balance between caution and clinical necessity reflects a more mature, evidence-informed approach to kidney care in the imaging era.

References

ACR Committee on Drugs and Contrast Media. “ACR Manual on Contrast Media.” American College of Radiology; 2024.

Davenport MS, et al. “Contrast material–induced nephrotoxicity and intravenous low-osmolality iodinated contrast material.” Radiology. 2013;267(1):94–105. Link

KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2021;11(4):1–115.

This chronic kidney disease FAQ was created to give newly diagnosed patients a clear and practical starting point. Each question below reflects the real concerns that patients often bring up during their first conversations with a kidney specialist. The answers are short, evidence-based, and written in plain language so you can understand what matters most right now.

Your Questions, Fast Answers and Deep Dive Links.

Q1. What are the most common early symptoms of CKD?

Most people don’t notice symptoms until later stages. Subtle signs may include fatigue, swelling in the ankles, foamy urine, or changes in blood pressure.

Read more: “I have CKD” – Gaining Strength through Understanding

Q2. How is chronic kidney disease usually diagnosed?

Doctors typically use blood tests (creatinine, eGFR), urine tests for protein, and sometimes imaging to check kidney structure. Many cases are first discovered during routine labs.

Read more: Next Best Steps After a CKD Diagnosis: Initial 3 Step Nephrology Evaluation

Q3. Can chronic kidney disease be reversed?

CKD generally cannot be reversed, but treatment and lifestyle changes can slow or even stop its progression. Early detection is the key to protecting kidney function.

Read more: When CKD Isn’t Really Chronic – 3 Important Categories of Acute Kidney Injury

Q4. What stage am I in, and what does that mean?

CKD is staged 1 through 5 based on eGFR. Early stages may not cause symptoms, while stage 5 usually requires dialysis or transplant. Knowing your stage helps guide monitoring and lifestyle focus.

Read more: CKD Stages 1 Through 5 and Why Does this Matter to Me?

Q5. Should I change my diet right away?

Not everyone needs a strict kidney diet at diagnosis. Your provider may recommend adjustments depending on labs (potassium, phosphorus, protein, sodium). Diet changes are individualized.

Read more: Improve Your Diet: The Impact of Nutritional Focus on Preserving Kidney Health

Q6. What lab values are most important to follow?

Key labs include creatinine/eGFR, urine protein, blood pressure, and electrolytes like potassium and phosphorus. These help track disease progression and guide care.

Read more: Understanding Your Labs: A Clear Guide to Creatinine, Potassium, and Beyond

Q7. Do all patients with CKD need dialysis?

No. Many patients live for years with stable kidney function and never require dialysis. Dialysis is considered when kidneys can no longer keep up with waste and fluid removal.

Read more: “What Is GFR in CKD and Why Is It important?”

Q8. What should I do after being diagnosed?

Stay engaged with your doctor, manage blood pressure and blood sugar, review medications (avoiding NSAIDS), and consider lifestyle changes like diet, exercise, and quitting smoking.

Read more: Targeted Therapy for Delaying Progression of CKD: 4 Standouts and More

Q9. Is chronic kidney disease hereditary?

Some causes (like polycystic kidney disease) are inherited, but most cases are due to diabetes, hypertension, or other acquired conditions. Family history may increase risk.

Read more: What Causes of Chronic Kidney Disease Should You Know About?

Q10. How often should I see my doctor now?

This depends on your stage of chronic kidney disease and lab results. Many patients in early stages are seen every 3–6 months; advanced stages may require more frequent monitoring.

Read more: What Does a Nephrologist Do—and Why You May Benefit from Seeing One?

Think of this page as a quick reference guide—something you can read today and then return to as new questions arise. For more detail on each topic, you’ll find links to full articles and tools that can help you take the next step with confidence.

• Additional FAQ can be found within the NKF Resource Center